Image_2_Loss of Cdc42 causes abnormal optic cup morphogenesis and microphthalmia in mouse.jpg by Katrina S. Hofstetter (17545425)

“…EdU incorporation is significantly downregulated. In addition, mitotic retinal progenitor cells mislocalize deeper, basal regions, likely contributing to decreased proliferation. …”

Image_2_Loss of Cdc42 causes abnormal optic cup morphogenesis and microphthalmia in mouse.jpg by Katrina S. Hofstetter (17545425)

“…EdU incorporation is significantly downregulated. In addition, mitotic retinal progenitor cells mislocalize deeper, basal regions, likely contributing to decreased proliferation. …”

Image_3_Loss of Cdc42 causes abnormal optic cup morphogenesis and microphthalmia in mouse.JPEG by Katrina S. Hofstetter (17545425)

“…EdU incorporation is significantly downregulated. In addition, mitotic retinal progenitor cells mislocalize deeper, basal regions, likely contributing to decreased proliferation. …”

<b>The inhibitory and anti-inflammatory effects of TMP269 on peste des petits ruminants virus replication</b> by miaomiao li (20222181)

“…TMP269, a selective class IIa HDAC inhibitor, plays an important role in cancer therapy and also modulates viral replication. …”

Table 2_Microbial diversity and community assembly in heavy metal-contaminated soils: insights from selenium-impacted mining areas.docx by Zhiyong Wang (313131)

“…Microbial diversity decreased as Se and other heavy metal concentrations increased. …”

Table 2_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 3_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 2_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Table 3_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 8_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tif by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 6_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 4_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tif by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 7_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 5_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Table 4_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Table 5_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Atorvastatin neuronal morphology data_CP.xlsxData set: neuronal morphology by Carolyn Pytte (20641508)

“…Our findings indicate that atorvastatin may affect neural cytoarchitecture in both newly formed and mature neurons, perhaps as a consequence of decreased cholesterol availability in the brain.…”

CBD treatment did not affect activity, anxiety, or improve aging-related declines in strength of SAMP8 mice. by Monica N. Goodland (22057339)

“…<p>A: The elevated maze test showed that 12 mos-old mice (red bar) and 4 mos-old mice (white bar) that received vehicle had similar anxiety levels to one another. 12 mos-old mice that received both 3 (blue bar) or 30 mg/Kg (gray bar) of CBD showed decreased anxiety compared to the 12 mos-old mice that received vehicle (red bar) (O-Veh) (N = 10 ~ 12 per group). …”

Image 2_Growth regulation mechanism of Rhododendron moulmainense to high-temperature stress: integrated physiological, transcriptomic, and metabolomic insights.jpg by Zaid Khan (625790)

“…The findings revealed that DEGs and DAMs regulating secondary metabolites (SM) in starch-sucrose metabolism, encoding SUS, TPS1, BAM1, sucrose, D-ribose, and D-fructose, and ABC transporters such as ABCC1, ABCC2, ABCG2, Thiamine, and Betaine were significantly higher in T42 to regulate the plant growth under HT. …”

Data file. by Maryam Khalaji (21743611)

“…The results showed that mental fatigue significantly decreased QE duration (Mean difference = −138.75 ms, p = .0009) and fixation duration (Mean difference = 67.50 ms, p = .001), indicating a detrimental effect on sustained attention. …”